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Objective: Chronic subdural hematoma (CSDH) is a common form of intracranial
hemorrhage with a substantial recurrence rate. Atorvastatin may reduce CSDH via
its anti-inflammatory and pro-angiogenesis effects, but its effectiveness for preventing
recurrent CSDH has never been explored. We hypothesized that atorvastatin is effective
in reducing recurrence of CSDH after surgery and identified determining factors predictive
of hematoma recurrence.
Methods: A prospective study was conducted in 168 surgical cases of CSDH.All
patients were randomly assigned to the group treated with atorvastatin or control group.
Clinically relevant data were compared between two groups, and subsequently between
the recurrence and non-recurrence patients. Multiple logistic regression analysis of the
relationship between atorvastatin treatment and the recurrence using brain atrophy,
septated and bilateral hematoma was performed.
Results: Atorvastatin group conferred an advantage by significantly decreasing the
recurrence rate (P = 0.023), and patients managed with atorvastatin also had a
longer time-to-recurrence (P = 0.038). Admission brain atrophy and bilateral hematoma
differed significantly between the recurrence and non-recurrence patients (P = 0.047
and P = 0.045). The results of logistic regression analysis showed that atorvastatin
significantly reduced the probability of recurrence; severe brain atrophy and bilateral
hematoma were independent risk factors for recurrent CSDH.
Conclusions: Atorvastatin administration may decrease the risks of recurrence.Patients
with severe brain atrophy and bilateral CSDH are prone to the recurrence.
Keywords: Chronic subdural hematoma, atorvastatin, recurrence
INTRODUCTION
Chronicsubdural hematoma (CSDH) is a common form of intracranial hemorrhage with a
recurrence rate after burr-hole surgery ranging from 9.2 to 26.5% (Wakai et al., 1990; Ernestus et al.,
1997; Nakaguchi et al., 2001; Amirjamshidi et al., 2007). The origin and enlargement of CSDH have
not been fully explained by any current hypothesis. Impaired angiogenesis in the neomembrane
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and localized inflammation may be important elements
in the development of CSDH (Hohenstein et al., 2005;
Javadi et al., 2011). Atorvastatin has pleiotropic effects on
restraining inflammation and promoting angiogenesis besides
its cholesterol-lowering function (Buttmann et al., 2007; Lu
et al., 2007; Matsumura et al., 2009; Araujo et al., 2010).
Although results from a preliminary clinical study showed that
the oral administration of atorvastatin is safe and effective in
treating CSDH, its effect on recurrence of CSDH has never
been explored. We hypothesized that atorvastatin is effective
in reducing recurrence after hematoma removal by restraining
inflammation and promoting membrane neovascularization,
which improves blood drainage. We tested this hypothesis by
investigating the efficacy of atorvastatin (20 mg/night, oral) for
treating patients with CSDH after burr-hole drainage.
METHODS
Patients
This prospective study comprised 168 patients with CSDH who
were enrolled from February 2013 to July 2015 under a human
subject protocol approved by the Jiangsu University Hospital
Medical Ethics Board. All patients and/or their family members
were thoroughly informed of the study and its risks. An informed
consent was obtained from each patient or his or her legal
representative.
Clinical data including age, sex, head injury history and
medical history were obtained on the day of diagnosis. Patients
enrolled in the study were evaluated using Markwalder’s Grading
Scale and Glasgow Coma Scale (MGS-GCS) on admission
(Markwalder et al., 1981). They were graded into the following
stages according to the criteria listed in Table 1.
Computed Tomography (CT) was performed before surgery
and repeated twice in the first month and then monthly until 3
months after surgery. Additional CT examination was performed
when necessary. The hematoma collection was classified as
hypodense, isodense, hyperdense, or mixed, on the basis of the
density of hematoma relative to brain tissue (Scotti et al., 1977).
Brain atrophy was classified into three stages: no or mild atrophy;
definite atrophy such as dilated sulci; severe atrophy such as
widely dilated sulci and subdural space (Kudo et al., 1992).
Inclusion and Exclusion Criteria
Patients were enrolled based on the following inclusion criteria:
age ≥ 18 years and evidence of supratentorial CSDH by CT;
patients with the following conditions were excluded from
the study: histories of liver failure, renal failure, disseminated
intravascular coagulation and previous recurrence; CSDH
resulting from tumor or blood disease; angiotensin converting
enzyme inhibitor (ACEI), estrogen, etizolam and steroid use
that may influence angiogenesis and promote blood circulation
within 2 weeks prior to the enrolment; and refusal to participate
in the study.
Design and Atorvastatin Therapy
All cases of CSDH underwent surgical intervention, including
trepanation of a single burr hole and irrigation of the hematoma
TABLE 1 | Grading criteria for patients enrolled in the study.
Patient’s grade Markwalder’s grading
scale
Glasgow coma scale
Grade 0 Normal neurological status
without any symptoms
Glasgow coma scale
score of 15
Grade 1 Without neurological
deficits, but with symptoms
such as headache or
unsteady gait
Glasgow coma scale
score of 15
Grade 2 Focal neurological deficits,
such as drowsiness or
disorientation, or variable
neurological deficits, such
as hemiparesis
Glasgow Coma Scale
score of 13 to 14
Grade 3 With stupor but appropriate
responses to noxious stimuli
and several focal
neurological signs such as
hemiplegia
Glasgow coma scale
score of 9 to 12
Grade 4 Coma with absent motor
responses to noxious stimuli
and decerebrate or
decorticate posturing
Glasgow coma scale
score of less than 9
Only patients with grades 0–3 CSDHwere selected for atorvastatin treatment in this study.
with saline solution under local anesthesia. After the irrigation,
a postoperative closed drainage system with a silicone tube
was inserted into the hematoma cavity. The drainage tube was
usually removed 2 days after surgery. All patients with bilateral
hematoma were treated 1 side at a time.
Threemedical assistants were appointed as study coordinators
responsible for group and drug assignments. All patients were
randomly assigned to the group treated with atorvastatin or
the control group after surgery. A single oral dose of 20mg
atorvastatin daily (Pfizer, USA) for 3 months was taken by
atorvastatin patients the next day. Patients were monitored for
blood cell counts, functions of coagulation system, liver, kidney,
neurological system, and gastrointestinal track, and symptoms
related to the medication during the course of treatment.
Aspirin or warfarin was discontinued after enrollment. If a
prothrombin time/international normalized ratio (PT/INR) on
admission was more than 1.5, vitamin K2 was administered
intravenously to the patient before surgery. PT/INR was
rechecked and vitamin K2 was repeated if the PT/INR was still
more than 1.5. All patients resumed taking the antiplatelet and/or
anticoagulant drugs 1 week after the operation, and the PT/INR
was controlled no more than 1.5.
Routine follow-up was generally conducted twice in the first
month andmonthly until 3 months after operation.When feeling
uncomfortable, the patients could visit back at any time.
Definition
We defined “recurrence” of CSDH as a subsequent increase
in hematoma volume in the ipsilateral subdural space with
neurological deficits, which was followed by another operation.
Some objective criteria were used to decide re-surgery: a sudden
increase in hematoma volume ≥ 10%, a mid-line displacement
Frontiers in Neuroscience | www.frontiersin.org 2 June 2016 | Volume 10 | Article 303
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of greater than 1 cm by CT scan, a decrease in GCS ≥ 2 or
deterioration in MGS-GCS ≥ 1. Time-to-recurrence was defined
as time from the first surgery to recurrence. The atorvastatin
treatment was discontinued if a recurrence occurred.
Statistical Analysis
Data were presented as Mean ± SD. Student t-test or Linear
Trend Chi-Square test were used to evaluate differences between
groups. A logistic regression model was used to determine
correlations between continuous or categorical variables and
independent factors affecting the recurrence. All statistical
analyses were carried out using SPSS for Windows version 18.0
(SPSS, Inc., Chicago, Illinois, USA), and significance was defined
as a P-value < 0.05.
RESULTS
The overall study profile is shown in Figure 1. All patients were
randomly placed into the atorvastatin group or the control group.
The demographic and clinical characteristics of the patients
are summarized in Table 2. The 2 groups were well matched.
Mean age of the participants was 64.61 ± 10.50 years, ranging
from 38 years to 84 years. Totally138 men and 30 women were
included, the sex ratio being 4.6:1. As expected, atorvastatin
group conferred an advantage by significantly decreasing the
recurrence rate (P = 0.023). Surprisingly, patients treated with
atorvastatin also had a longer time-to-recurrence (P = 0.038).
The 2 groups in our study were similar in age, gender, history
of head injury, medical history, MGS-GCS scores and CT
performance on admission (Table 2).
Table 3 shows baseline characteristics comparison between
the recurrence group and no recurrence group. Demographic
variables such as age, sex, head injury and medical history,
MGC-GCS scores and CT density at admission demonstrated no
difference between 2 groups. The ratio of severe brain atrophy
was significantly higher in the recurrence group (P = 0.047).
Patients with CSDH recurrence tended to have a septated
hematoma on admission, although not statistically significant
(P = 0.060). There existed a significantly higher ratio of bilateral
hematoma in the non-recurrence group (P = 0.045). Recurrence
group was significantly associated with higher rate of atorvastatin
use (P = 0.023).
We performed a multivariate logistic regression analysis and
found that atorvastatin was an independent protective factor
for the recurrence of CSDH (odds ratio, 0.252; 95% confidence
interval, 0.090–0.702; P = 0.008). Compared with definite
atrophy on admission CT, no or mild atrophy was found to
have a significant relationship with non-recurrence (P = 0.019),
whereas severe atrophy was considered as an independent
risk factor for the recurrence (P = 0.034). Although septated
hematoma was not significantly associated with recurrence,
patients with septated hematoma had an odds ratio of 3.417 (95%
confidence interval, 0.931–12.536; P = 0.064). After adjustment
for other factors, bilateral hematoma was demonstrated as an
independent risk factor for the recurrence of CSDH (P = 0.004)
(Table 4).
TABLE 2 | The demographic and clinical characteristics of 2 groups.
Atorvastatin Control P-value
Age 65.66 ± 10.78 63.33 ± 10.08 0.152
Women 15/92 (16.3%) 15/76 (19.7%) 0.563
Head injury 63/92 (68.5%) 57/76 (75.0%) 0.352
MEDICAL HISTORY
Hypertension 30/92 (32.6%) 28/76 (36.8%) 0.566
Diabetes 14/92 (15.2%) 15/76 (19.7%) 0.440
Arrhythmia 9/92 (9.8%) 13/76 (17.1%) 0.161
Cerebrovasculer accident 8/92 (8.7%) 10/76 (13.2%) 0.352
Aspirin history 11/92 (12.0%) 14/76 (18.4%) 0.241
Warfarin history 8/92 (8.7%) 10/76 (18.4%) 0.352
ADMISSION
MGS-GCS 0.878
Grade 0 4/92 (4.3%) 4/76 (5.3%)
Grade 1 19/92 (20.7%) 12/76 (15.8%)
Grade 2 26/92 (28.3%) 24/76 (31.6%)
Grade 3 36/92 (39.1%) 32/76 (42.1%)
Grade 4 7/92 (7.6%) 4/76 (5.3%)
CT density 0.192
Hypodense 16/92 (17.4%) 11/76 (14.5%)
Isodense 42/92 (45.7%) 27/76 (35.5%)
Hyperdense 22/92 (23.9%) 30/76 (39.5%)
Mixed 12/92 (13.0%) 8/76 (10.5%)
Brain atrophy 0.392
No/mild atrophy 32/92 (34.8%) 34/76 (44.7%)
Definite atrophy 28/92 (30.4%) 18/76 (23.7%)
Severe atrophy 32/92 (34.8%) 24/76 (31.6%)
Septated 18/92 (19.6%) 20/76 (26.3%) 0.298
Laterality 0.744
Unilateral 77/92 (83.7%) 65/76 (85.5%)
Bilateral 15/92 (16.3%) 11/76 (14.5%)
Recurrence 8/92 (8.7%) 16/76 (21.1%) 0.023
Time-to-recurrence 35.75 ± 12.49 24.31 ± 11.68 0.038
Data are mean ± SD, n/N(%); MGS-GCS, Markwalder’s Grading Scale and the Glasgow
Coma Scale; CT, Computed Tomography.
DISCUSSION
The aim of this study was to evaluate the effect of atorvastatin on
CSDH recurrence after surgery and identify risk factors for the
recurrence of CSDH. The results indicated that patients managed
with atorvastatin had a lower rate of recurrence and, fortunately,
the time interval between the first surgery and recurrence was
also postponed after atorvastatin use. Additionally, multiple
logistic regression analysis showed that severe atrophy and
bilateral hematoma on admission were independent risk factors
for the recurrence.
Atorvastatin Therapy
Atorvastatin, one of the 3-Hydroxy-3-methylglutaryl (HMG)-
COA reductase inhibitors, is the first-line treatment for high
cholesterol patients and has been demonstrated to improve
angiogenesis and increase circulating endothelial progenitor cells
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FIGURE 1 | Overall study profile.
(EPCs), which are critical for the formation of new blood
vessels (Youssef et al., 2002). It has also been shown to inhibit
inflammation and decrease levels of pro-inflammatory molecules
(Araujo et al., 2010). Previous studies demonstrated that the
most potent anti-inflammatory facilitation without the risk of
hemorrhage was initiated by the low dose but not the high dose
of atorvastatin (Urbich et al., 2002; Chen et al., 2003). CSDH
patients responded well to the dose of 20mg daily atorvastatin
(Wang et al., 2014). Consequently, this dose was chosen to be
applied in the present study.
A previous study indicated that inflammatory activities in
the hematoma might play a role in the risk of a recurrence
of CSDH (Pripp and Stanisic, 2014). In addition, the other
prospective study reported that brain trauma caused the onset
of an inflammatory process within the dural border cell layer
and high level of inflammatory cytokines were significantly
correlated with CSDH recurrence (Frati et al., 2004). However,
no studies concerning atorvastatin in the prevention of CSDH
recurrence have been reported. It is based on known effects
of statins on inflammation and angiogenesis that we designed
this atorvastatin treatment trial for the recurrence. This is
the first study that evaluates the effect of atorvastatin on the
postoperative recurrence of CSDH using a black-controlled
comparison prospectively.
Our findings showed that the recurrent rates of CSDH
declined significantly from 21.1% in the control group to less than
10% of patients treated with atorvastatin, which accords with
results from a preliminary study. Dong Wang and co-workers
reported that 2 patients with recurrent CSDH from prior surgery
had a complete response after atorvastatin use, indicating that
atorvastatin is effective not only for patients with primary CSDH,
but also for those with recurrent hematoma (Wang et al., 2014).
These findings are consistent with a positive effect of atorvastatin
in prevention of formation and re-accumulation of CSDH, and
their use could avoid some devastating complications in surgical
intervention. In our study, significant differences in the time-
to-recurrence between groups also suggested the effectiveness
of atorvastatin therapy in recurrent CSDH. In addition, the
logistic regression model established atorvastatin as one strong
protective factor associated with recurrence.
Brain Atrophy
There were more patients with severe atrophy and less with no
or mild atrophy in the recurrent patients. Taking definite atrophy
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TABLE 3 | The demographic and clinical characteristics of 2 groups.
Recurrence No recurrence P-value
Age 66.92 ± 7.73 64.22 ± 10.87 0.246
Women 6/24 (25.0%) 24/144 (16.7%) 0.324
Head injury 16/24 (66.7%) 104/144 (72.2%) 0.577
MEDICAL HISTORY
Hypertension 10/24 (41.7%) 48/144 (33.3%) 0.427
Diabetes 7/24 (29.2%) 22/144 (15.3%) 0.096
Arrhythmia 3/24 (12.5%) 19/144 (13.2%) 0.926
Cerebrovasculer accident 2/24 (8.3%) 16/144 (11.1%) 0.684
Aspirin history 2/24 (8.3%) 23/144 (16.0%) 0.330
Warfarin history 3/24 (12.5%) 15/144 (10.4%) 0.760
ADMISSION
MGS-GCS 0.522
Grade 0 1/24 (4.2%) 7/144 (4.9%)
Grade 1 2/24 (8.3%) 29/144 (20.1%)
Grade 2 8/24 (33.3%) 42/144 (29.2%)
Grade 3 10/24 (41.7%) 58/144 (40.3%)
Grade 4 3/24 (12.5%) 8/144 (5.6%)
CT density 0.614
Hypodense 6/24 (25.0%) 21/144 (14.6%)
Isodense 9/24 (37.5%) 60/144 (41.7%)
Hyperdense 7/24 (29.2%) 45/144 (31.3%)
Mixed 2/24 (8.3%) 18/144 (12.5%)
Brain atrophy 0.047
No/mild atrophy 5/24 (20.8%) 61/144 (42.3%)
Definite atrophy 6/24 (25.0%) 40/144 (27.8%)
Severe atrophy 13/24 (54.2%) 43/144 (29.9%)
Septated 9/24 (37.5%) 29/144 (20.1%) 0.060
Laterality 0.045
Unilateral 17/24 (70.8%) 125/34 (86.8%)
Bilateral 7/24 (29.2%) 19/144 (13.2%)
Atorvastatin 8/24 (33.3%) 84/144 (58.3%) 0.023
Data are mean ± SD, n/N(%); MGS-GCS, Markwalder’s Grading Scale and the Glasgow
Coma Scale; CT, Computed Tomography.
TABLE 4 | Logistic regression analysis of factors related to recurrence.
Factor OR(95% CI) P-value
Atorvastatin 0.252 (0.090–0.702) 0.008
Brain atrophy*
No/mild atrophy 0.067 (0.007–0.642) 0.019
Severe atrophy 4.192 (1.111–15.819) 0.034
Septated 3.417 (0.931–12.536) 0.064
Bilateral 28.860 (2.855–291.692) 0.004
OR, odds ratio; CI, confidence interval. *Definite atrophy was used as the reference group
for brain atrophy.
as the reference level, multivariate analysis revealed that no/mild
atrophy was a protective predictor for recurrence, whereas severe
atrophy was considered as a recurrence-related risk factor. Brain
atrophy has been well described as being a risk factor for both
occurrence and recurrence of CSDH (Yamamoto et al., 2003;
Amirjamshidi et al., 2007; Torihashi et al., 2008). This has
been explained by examining brain elastance. Higher elastance
is associated with increasing age, atrophy and persistence of a
subdural space (Fukuhara et al., 1996; Mori and Maeda, 2001).
Septated Hematoma
This study found a higher but non-significant recurrence rate in
patients with septated hematoma on admission. A previous study
demonstrated that a significantly higher postoperative recurrence
rate was found to be associated with separated type on CT
scans obtained within 4 days after surgery, whereas variables
on preoperative CT scans were not significantly associated with
the recurrence (Stanisic et al., 2005). It is understandable that
patients with septations treated with a thorough resection might
experience a lower CSDH recurrence. Thus, a considerable
number of cases appeared to need craniotomy and resection
of intrahematomal membrane for complete recovery in CSDH
(Tanikawa et al., 2001). Taking these findings together, it is
not strange that septations may play a role in increasing the
recurrence rate of CSDH. At least in the present study, we
could not conclude septated hematoma is a risk factor for the
recurrence of CSDH.
Bilateral CSDH
Bilateral CSDH has been considered to be a risk factor
for CSDH recurrence in previous studies (Robinson, 1984;
Probst, 1988). The recurrence rate in patients with bilateral
CSDHs has been reported to be significantly higher than
that in patients with unilateral CSDHs (Kung et al., 2012).
A large-scale study of 236 CSDH cases by Penchet et al.
showed remarkable statistical significance in postoperative
recurrence rate between the unilateral and bilateral ones
(Penchet et al., 1998). In addition, study has shown that
bilateral CSDHs have the potential for rapid and progressive
aggravation (Kurokawa et al., 2005). In our study, the results
of logistic regression demonstrated that bilateral CSDH was
an independent predictor for recurrent CSDH. Patients with
bilateral CSDH tend to have previous brain atrophy, which
may lead to poor brain reexpansion after the operation.
Poor brain reexpansion has been shown to be correlated
with recurrence, and it is thought to create the potential
for reaccumulation of the hematoma (Torihashi et al.,
2008).
CONCLUSIONS
Atorvastatin administration may reduce the recurrent risks
of CSDH. Severe brain atrophy and bilateral hematoma were
independent predictors for the recurrence.
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